Why the study?
Do abnormal serum potassium levels increase short-term mortality in patients with atrial fibrillation co-treated with diuretics and rate- or rhythm-controlling drugs?
Do abnormal serum potassium levels increase short-term mortality in patients with atrial fibrillation co-treated with diuretics and rate- or rhythm-controlling drugs?
Answers are grounded in this paper and cite their sources.
A U-shaped association exists between serum potassium levels and short-term mortality in AF patients on diuretics and rate/rhythm control, suggesting an optimal target of 4.1-4.4 mmol/L.
This editorial refers to ‘Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs’, by L. Hagengaard et al., on page 137. Homeostasis of potassium in humans is crucial to proper functioning of the cardiovascular system, especially cardiac electrical stability. Potassium balance is achieved when renal excretion of potassium is replaced by dietary intake, estimated to be 50–150 mmol/day (1.4–4.3% of today body potassium). This balance, in conjunction with hormonally regulated intra-/extracellular shifting of potassium, largely achieved by the Na+–K+-ATPase, results in 98% of potassium being harboured in the intracellular space and its serum level maintained at 3.5–5.3 mmol/L.1 What constitutes the optimal serum level of potassium in patients with cardiovascular diseases has long been a key question, but without any clear answers. In clinical practice, the picture is often complicated: with a dynamic interplay between underlying comorbid conditions (such as renal failure) and drugs (diuretic therapies, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, potassium supplementation, insulin therapy), as well as the intrinsic myocardial susceptibility to electrolyte imbalances in patients with diseased myocardium. However, how serum potassium levels affect patients with arrhythmic predisposition, such as those with known cardiac arrhythmias and/or on anti-arrhythmic agents, remain incompletely understood. The untoward effects of diuretic therapy-related hypokalaemia on cardiovascular outcomes have been described. A previous study revealed that any diuretic use was associated with 37% excess risk of arrhythmic deaths amongst patients with left ventricular dysfunction, but such an adverse risk had not been seen in those treated with potassium-sparing diuretics.2 Furthermore, patients with hypertension who were treated with higher doses of thiazide diuretics had increased risks of primary cardiac arrest compared with those on beta-blockers, but this adverse relationship was abolished, or even reversed, if they were concomitantly prescribed potassium-sparing diuretics.3 In this issue of the European Heart Journal – Cardiovascular Pharmacotherapy, Hagengaard et al.4 provide important insights into this topic, through dissecting the mortality risks associated with graduated levels of potassium in patients with atrial fibrillation (AF) or flutter, treated with diuretics and concurrently receiving a rate-/rhythm-controlling agent. In a large sample (n >14 000) of Danish patients with newly diagnosed AF co-treated with diuretics and rate-/rhythm-controlling agents, they observed an elevated risk of all-cause mortality at 90 days post-discharge which was independently linked to bidirectional fluctuations of the serum potassium level. The excess risks associated with overt hypokalaemia (<3.5 mmol/L) and hyperkalaemia (>5.0 mmol/L) were both increased (hazards ratios of 2.0 and 1.9, respectively). In agreement with findings in other cardiovascular populations of interest, including those with chronic heart failure5 and myocardial infarction,6 these findings are not entirely unexpected. The reported adverse risks were also of magnitudes comparable with previous studies. What is more striking in the current study by Hagengaard et al. was the conferred excess risks of all-cause and cardiovascular mortality (20% and 25%, respectively) associated with only a slightly raised potassium level of 4.5–4.7 mmol/L or, conversely, a low–normal potassium level (3.5–3.7 mmol, increased risks of all-cause mortality by 28%, no difference in cardiovascular mortality), using a reference comparison of 4.1–4.4 mmol/L. Such a U-shaped association with mortality showed a bidirectional dose–response, and suggests that patients with AF co-treated with diuretic therapy and a rate-/rhythm-controlling agent might benefit from keeping their serum potassium within a rather narrow ‘safety zone’. While drug-potentiated pro-arrhythmic risks of potassium fluctuations, such as digitalis toxicity in hypokalaemia, have been described in various settings,1,7 the authors found no significant effect modification of their main findings by the rate-/rhythm-controlling agents. The described findings have important clinical implications for practice. Despite lacking a unified consensus, clinical evidence thus far had favoured the serum potassium level to be kept between 4.5 mmol/L and 5.5 mmol/L in patients with acute myocardial infarction or heart failure.1 Based on the findings of this current study, the optimal serum potassium level of AF patients co-treated with diuretic therapy and rate-/rhythm-controlling agents appears to be 4.1–4.4 mmol/L. Interestingly, from the data presented here, the proportion of subjects with AF found to have extreme levels of serum potassium (respectively the highest and lowest serum categories combined, i.e. ≤3.7 mmol/L or ≥4.8 mmol/L) was greater amongst those on diuretic therapy, compared with those without diuretic therapy (31.8% vs 19.3%), reiterating the preponderance of these subjects being subject to cardiac risks of serum potassium fluctuations. Whether stringent clinical control of serum potassium through monitoring and corrections might translate into actual benefits in clinical outcomes will need to be tested in upcoming randomized clinical trials. From the electrophysiological point of view, hypokalaemia causes resting membrane hyperpolarization and compromises repolarization reserve of cardiomyocytes through a number of mechanisms. Hypokalaemia impedes K+ channel conductance and prolongs action potential duration. At the same time, it inhibits Na+–K+-ATPase, resulting in intracellular Na+ accumulation and suppressed activity of the Na+–Ca2+ exchanger. The consequential intracellular Ca2+ loading leads to activation of calmodulin kinase and induction of the late Na+ and Ca2+ currents. The net effects are prolonged action potential duration, reduced repolarization reserve with increased risk of early afterdepolarizations, and delayed afterdepolarizations, as well as enhanced automaticity.7 These thus lead to increased risks of cardiac arrhythmias including torsades de pointes and polymorphic ventricular tachycardia. In the presence of myocardial ischaemia in particular, cardiomyocyte potassium extrusion results in hypopolarization, interstitial hyperkalaemia, and reduced arrhythmic threshold, providing further substrate for ventricular arrhythmias.8,9 Last, but not least, adequate potassium may have numerous essential roles in protection against cardiovascular diseases via non-electrophysiological pathways, including inhibition of thrombogenesis and platelet aggregation, reduction of formation of free radicals, proliferation of vascular smooth muscle cells, and monocyte adherence, as well as reduced hypertension.1 On the other hand, hyperkalaemia, through resting membrane depolarization and global shortening of action potential duration, causes conduction block, asystole, and ventricular arrhythmias, and also promotes reentrant tachyarrhythmia. The detrimental effects of hyperkalaemia have been well described elsewhere.7 Based on the current findings, clinicians should exercise caution in avoiding iatrogenic risks of serum potassium fluctuations in AF patients co-treated with diuretics and rate-/rhythm-controlling agents. Certainly, this study will lead to further endeavours in addressing several unanswered key questions, the first of which is the clinical applicability of stringent surveillance and correction of serum potassium in improving clinical outcomes of AF patients. Secondly, the relationships between anti-arrhythmic drugs and serum potassium alterations in pro-arrhythmicity of AF patients will need to be further explored. The serum measurement of potassium should be ideally related back to the intuitively important balance between dietary potassium intake and, if possible, studies of urinary potassium excretion. Finally, potassium homeostasis is never a monologue, but part and parcel of a wider, orchestrated network of homeostasis with other electrolytes, namely sodium, calcium, and magnesium.9 More often overlooked, severe hypomagnesaemia per se may cause spatially heterogeneous prolongation of repolarization, resulting in increased risk of sudden cardiac death.10 Investigated thoroughly, these parameters will also yield insights into the holistic risk management of cardiac patients regarding clinical electrolyte control to minimize their cardiac risk. Conflict of interest: none declared. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal – Cardiovascular Pharmacotherapy or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: